40 Results

People

  1. Riely
    Riely
  2. Drilon
    Drilon
  3. Kris
    Kris
  4. Adusumilli
    Adusumilli
  5. Arbour
    Arbour
  6. Bains
    Bains
  7. Chakravarty
    Chakravarty
  8. Imber
    Imber
  9. Isbell
    Isbell
  10. Jones
    Jones

Groups

  1. Department of Medicine (31)
  2. Solid Tumor Oncology Division (30)
  3. Thoracic Oncology (29)
  4. Department of Pathology and Laboratory Medicine (7)
  5. Radiology, Department of (5)
  6. Weinberg Fellows (5)
  7. Body Imaging Service (4)
  8. Early Drug Development Service (4)
  9. Graduate Medical Education (4)
  10. Sloan Kettering Institute Postdocs (4)
  1. "alectinib"
Formats
  1. Journal Article (25)
  2. Review (7)
  3. Meeting Abstract (3)
  4. Conference Paper (2)
  5. Editorial (1)
  6. Guidelines (1)
  7. Research Letter (1)
Groups
  1. Department of Medicine (31)
  2. Solid Tumor Oncology Division (30)
  3. Thoracic Oncology (29)
  4. Department of Pathology and Laboratory Medicine (7)
  5. Radiology, Department of (5)
  6. Weinberg Fellows (5)

More Groups

People
  1. Gregory Riely (12)
  2. Alexander Drilon (11)
  3. Mark Kris (3)
  4. Adam Schoenfeld (2)
  5. Alison Schram (2)
  6. Andrew Plodkowski (2)

More People

Years
  1. 2025 (3)
  2. 2024 (4)
  3. 2023 (7)
  4. 2022 (4)
  5. 2021 (1)
  6. 2020 (3)

More Years

Publications
  1. Journal of Thoracic Oncology (8)
  2. Cancer Discovery (3)
  3. Nature Reviews Clinical Oncology (3)
  4. Blood (2)
  5. JTO Clinical and Research Reports (2)
  6. Journal of Clinical Oncology (2)

More Publications

Publishers
  1. Elsevier Inc. (9)
  2. American Association for Cancer Research (4)
  3. Nature Publishing Group (4)
  4. Elsevier Science, Inc. (3)
  5. American Society of Clinical Oncology (2)
  6. American Society of Hematology (2)

More Publishers

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Order of treatment with ALK inhibitors and its effect on people with lung cancer in the real world: A plain language summary
    Editorial

    Bauman, J. R.; Liu, G.; Preeshagul, I.; Melosky, B.; Abrahami, D.; Li, B.; Thomaidou, D.; Krulewicz, S.; Rupp, M.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Determinants of successful minimally invasive surgery for resectable non–small cell lung cancer after neoadjuvant therapy
    Conference Paper

    Chu, N. Q.; Tan, K. S.; Dycoco, J.; Adusumilli, P. S.; Bains, M. S.; Bott, M. J.; Downey, R. J.; Gray, K. D.; Huang, J.; Isbell, J. M.; more...
    Mosby Elsevier (2025)

    Fulltext@MSK | Save
  • Overview of molecular prognostication for common solid tumor histologies – What the surgeon should know
    Journal Article

    Goodwin, C. R.; De la Garza Ramos, R.; Bettegowda, C.; Barzilai, O.; Shreyaskumar, P.; Fehlings, M. G.; Laufer, I.; Sahgal, A.; Rhines, L. D.; Reynolds, J. J.; more...
    Global Spine Journal (2025)

    Fulltext@MSK | Save
  • NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations
    Journal Article

    Lin, J. J.; Horan, J. C.; Tangpeerachaikul, A.; Swalduz, A.; Valdivia, A.; Johnson, M. L.; Besse, B.; Camidge, D. R.; Fujino, T.; Yoda, S.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • Tyrosine kinase inhibitors with and without up-front stereotactic radiosurgery for brain metastases from EGFR and ALK oncogene-driven non-small cell lung cancer (TURBO-NSCLC)
    Journal Article

    Pike, L. R. G.; Miao, E.; Boe, L. A.; Patil, T.; Imber, B. S.; Myall, N. J.; Pollom, E. L.; Hui, C.; Qu, V.; Langston, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: Consensus recommendations from the international association for the study of lung cancer
    Review

    Spicer, J. D.; Cascone, T.; Wynes, M. W.; Ahn, M. J.; Dacic, S.; Felip, E.; Forde, P. M.; Higgins, K. A.; Kris, M. G.; Mitsudomi, T.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer
    Journal Article

    Bauman, J. R.; Liu, G.; Preeshagul, I.; Liu, S. V.; Melosky, B.; Abrahami, D.; Li, B.; Thomaidou, D.; Duncan, K.; Krulewicz, S.; more...
    Lung Cancer (2024)

    Fulltext@MSK | Save
  • NAUTIKA1 study: Preliminary efficacy and safety data with neoadjuvant alectinib in patients with stage IB-III ALK+ NSCLC
    Meeting Abstract

    Lee, J. M.; Toloza, E. M.; Pass, H. I.; Johnson, B. E.; Heymach, J. V.; Sholl, L.; Saqi, A.; Travis, W. D.; Wistuba, I.; Lin, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Spontaneous bilateral chylothorax development during alectinib therapy for ALK-rearranged NSCLC—A case report
    Journal Article

    Bajaj, S.; Chow, A.; Drilon, A.; Kalchiem-Dekel, O.
    JTO Clinical and Research Reports (2023)

    Fulltext@MSK | Save
  • Advances in CAR T cell therapy for non-small cell lung cancer
    Review

    Ma, H. Y.; Das, J.; Prendergast, C.; De Jong, D.; Braumuller, B.; Paily, J.; Huang, S.; Liou, C.; Giarratana, A.; Hosseini, M.; more...
    Current Issues in Molecular Biology (2023)

    Fulltext@MSK | Save